Enzo Biochem Inc. [ENZ] has traded in a range of $1.56 to $4.85 in the last 1 year. As of this writing, the stock is at $2.16, down -17.24%. To check whether the stock’s short-term amount has a thrust, its good to check stock’s recent movement. Over the last week, ENZ shares are -3.57% down with the monthly amount drift of -7.69% and seems bad in a long time frame.

On 13, October 2020, Enzo Biochem Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update. According to news published on Yahoo Finance, Company reports $19.5 million in revenue and EPS of ($0.07) in the fourth quarter with significant margin expansion supported by rapid response to COVID-19 market opportunities.

Analyst Birdseye View:

The most recent analyst activity for Enzo Biochem Inc. [NYSE:ENZ] stock was on September 23, 2009, when it was Initiated with a Mkt outperform rating from Rodman & Renshaw, which also raised its 12-month price target on the stock to $14. Before that, on October 18, 2011, Rodman & Renshaw Recapitulated a Mkt outperform rating and elevated its amount target to $5. On September 13, 2007, Lazard Capital Initiated a Buy rating and boosted its price target on this stock to $19.

In the past 52 weeks of trading, this stock has oscillated between a low of $1.56 and a peak of $4.85. Right now, the middling Wall Street analyst 12-month amount mark is $5.50. At the most recent market close, shares of Enzo Biochem Inc. [NYSE:ENZ] were valued at $2.16.

FUNDAMENTAL ANALYSIS

Enzo Biochem Inc. [NYSE:ENZ] most recently reported quarterly sales of 16.9 billion, which represented growth of -14.20%. This publicly-traded organization’s revenue is $162,340 per employee, while its income is $4,978 per employee. This company’s Gross Margin is currently 28.80%, its Operating Margin is -40.80%, its Pretax Margin is +3.07, and its Net Margin is +3.07. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at 2.39, 2.98, -28.02 and 2.89 respectively.

If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 5.49 and the whole liability to whole assets at 4.68. It shows enduring liability to the whole principal at 5.06 and enduring liability to assets at 0.04 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 2.08 points at 1st support level, the second support level is making up to 2.00. But as of 1st resistance point, this stock is sitting at 2.26 and at 2.36 for 2nd resistance point.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Enzo Biochem Inc. [NYSE:ENZ] is 2.30. Now if looking for a valuation of this stock’s amount to sales ratio it’s 2.29 and it’s amount to book ratio is 2.16.

Insider Stories

The most recent insider trade was by CLEMENS PETER J IV, 10% Owner, and it was the purchase of 4000.0 shares on Feb 18. CLEMENS PETER J IV, the 10% Owner, completed a purchase of 6000.0 shares on Feb 14.